Enzalutamide vs Bicalutamide in CRPC:The TERRAIN trial
Patient population:
Primary endpoints:
l
id
•
375 men with progressive
mCRPC
•
Asymptomatic/
Progression‐free
survival:
Enza utam e
160 mg/day
(capsules)
n 184
R
A
N
mildly symptomatic
•
Chemotherapy‐naïve
N t
i
t f
‐
Radiographic
progression (central
review)
=
D
O
M
I
•
o requ remen or
steroids
‐
Skeletal‐related
events
‐
Change to a new anti‐
Bicalutamide
Z
E
D
Exluded:
‐Progression on anti‐
androgen therapy
neoplasic therapy
‐
Death
N=191
1:1
Shore ND, et al. Lancet Oncol 2016
